Pfizer Completes Acquisition of Nimenrix and Mencevax from GlaxoSmithKline
October 1, 2015– Pfizer Inc. today announced that it has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcalACWY vaccines Nimenrix and Mencevax.
“The addition of Nimenrix and Mencevax help us to fulfill our vision to protect lives with innovative vaccines to fight serious diseases worldwide,” said Susan Silbermann, president and general manager, Pfizer Vaccines. “These vaccines addhigh-quality and complementary vaccines to our existing portfolio, allowing us to reach a broader global population.”
“With these two additions to the Pfizer Vaccine Portfolio, this will help us in fighting diseases better and ensuring that these Vaccines are helpful in protecting against meningococcal disease that can lead to disability and death. Meningococcal vaccination is mandatory for Hajj pilgrims and Mancevax has been the vaccine of choice in Pakistan for that purpose,” said Asim Sarfraz, Business Unit Lead for Vaccines at Pfizer Pakistan.
Pfizer Inc. has completed the global acquisition on October 1. In Pakistan, the two companies are working together to devise a plan for a smooth transition of these drugs.
About Nimenrix and Mencevax
Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine) is a single dose meningococcal ACWY-TT (tetanus toxoid) conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. It is indicated for all age groups above one year of age. Launched three years ago, Nimenrix is currently registered and approved for sale in 63 countries across the European Economic Area (EEA 30), Canada, Australia and Emerging Markets, with registrations under review in another 17 countries across Africa, Asia, Eastern Europe and the Middle East.
Mencevax (meningococcal polysaccharide serogroups A, C, Y and W-135 vaccine) is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers in countries where the disease is endemic or highly epidemic. Mencevax is indicated for use across all age groups from 2 years of age, and is currently registered and approved in 78 countries across Africa, Asia, Australia, Europe, Latin America, Middle East and New Zealand.
Pfizer Pakistan: Working together for a healthier world™
Pfizer has been working for the health and wellbeing of patients in Pakistan for more than 50 years. Our business in Pakistan is part of the global Pfizer Inc. operations, first founded in 1849 in New York, USA. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our operations in Pakistan, please visit us at www.pfizer.com.pk